Delveinsight

SEPTEMBER 23, 2021

The biotech has evolved a T-cell receptor-like antibody to damage a selected immune checkpoint in oncology. 858 Therapeutics closes USD 60 Million series A round to drug RNA modulation. Now, they are ready for their next venture, which is launching RNA biotech 858 Therapeutics with a USD 60 million Series A fundraising.

RNA 61

RNA Gene Therapy Gene Protein 61

Drug Discovery World

MAY 17, 2024

The top stories: Gene therapy cures profound genetic deafness within 24 weeks The investigational gene therapy DB-OTO improved hearing to normal levels in a child (dosed at 11 months of age) within 24 weeks, according to trial data presented at the American Society of Gene and Cell Therapy (ASGCT) annual conference.

Gene Therapy 52

Gene Therapy Gene Drugs In-Vivo 52

Drug Discovery World

DECEMBER 21, 2023

DDW’s top 10 most popular articles for 2023 reflect the key subjects in drug discovery and development. Other biotechnologies coming to the fore this year were antibody-drug conjugates and CRISPR gene editing. Read the article – Three trends in the antibody-drug conjugate (ADC) market Expert view: What’s next for cell and gene therapy?

Gene Therapy 59

Gene Therapy Gene Antibody FDA Approval 59

pharmaphorum

OCTOBER 22, 2020

The company has joined forces with Atea Pharmaceuticals to develop, manufacture and distribute Atea’s investigational oral direct-acting antiviral AT-527. AT-527 works by blocking the viral RNA polymerase enzyme needed for viral replication. The post Roche to co-develop remdesivir rival in partnership with Atea appeared first on.

Development 66

Development Branding Manufacturing RNA 66

pharmaphorum

FEBRUARY 9, 2021

million ($22 million) in second-round financing as it prepares to start clinical trials of its lead drug candidate INT-1B3 for solid tumours. The start of dosing in the phase 1/1b trial of the drug has been delayed by the COVID-19 pandemic, but recruitment of the target 80 participants with advanced solid tumours is reported to be ongoing.

Trials 59

Trials Gene Silencing RNA Gene Expression 59

Drug Discovery World

OCTOBER 11, 2023

The DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances ’ will feature an expert panel discussion on new drug discovery and development concepts and tools in cancer research. The free two-hour Summit, hosted by DDW, will take place online on 16 November at 7AM PDT / 10AM EDT / 3PM GMT / 4PM CET.

Research 52

Research Antibody RNA Engineer 52

Pharmaceutical Technology

JULY 5, 2022

The team also found that the oral compound, RG7834, developed by Hoffmann-La Roche, hindered replication at a crucial step, preventing the virus from infecting liver cells. They also noted how the oral treatment could lower the ability of the virus to cause liver injury in mice genetically modified to develop HAV infection and disease.

Protein 130

Protein RNA Genome Genomics 130

XTalks

NOVEMBER 7, 2022

Gleich, MD, FACS, Senior Vice President, Medical Department, and Dr. Christopher Huth, PhD, Senior Clinical Trial Manager, Clinical Trial Management. Liquid Biopsy Use in Oncology Clinical Trials. Another method to isolate CTCs is by antibody targeting of white blood cells for removal, followed by collection of untagged CTCs.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. The Companies expect interim results from this trial in the third quarter of 2021. MRT5500 is being developed under a collaboration and license agreement between Sanofi Pasteur and Translate Bio.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Delveinsight

AUGUST 26, 2021

Seattle biotech firm Shape Therapeutics has signed a deal potentially exceeding USD 3 billion with pharma giant Roche to bolster the development of gene therapies for Alzheimer’s and Parkinson’s disease. Shape’s RNA editing technologies can modify the RNA sequence, which makes the body’s protein building blocks.

Vaccination 98

Vaccination Vaccine Gene Therapy RNA 98

pharmaphorum

JANUARY 7, 2022

NI006 is an antibody that binds to the misfolded forms of the transthyretin protein that form the fibrils, and cause them to be cleared away by immune cells like macrophages. Antisense drug eplontersen – which is forecast to become a $1 billion-plus product if approved – is being developed for both ATTR cardiomyopathy and polyneuropathy.

Antibody 116

Antibody Licensing Licensing Protein 116

XTalks

NOVEMBER 30, 2023

Global entities such as the WHO, the Global Fund and the Joint United Nations Programme on HIV/AIDS (UNAIDS) have developed comprehensive strategies aligned with Sustainable Development Goal (SDG) target 3.3, These findings signify a significant step forward in the development of AGT103-T as a potential gene therapy for HIV.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. Clover plans to initiate a global phase 2/3 trial in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

pharmaphorum

SEPTEMBER 16, 2020

Both of these vaccines are based on RNA and in phase 3 and phase 1 testing, respectively. The amount due to be awarded by Dessau-based IDT Biologika – whose non-replicating viral vector shot is further back in development – is still being discussed, according to German broadcaster Deutsche Welle.

Vaccination 86

Vaccination Vaccine RNA Trials 86

The Pharma Data

JANUARY 20, 2021

-based Gritstone Oncology is developing a novel COVID-19 vaccine based on adenovirus and messenger-RNA technology designed to combat future variants of the coronavirus.

Vaccination 52

Vaccination Vaccine RNA Protein 52

XTalks

JULY 14, 2022

Uncontrolled gout is defined as gout that is unmanageable and/or develops resistance to conventional therapies. Krystexxa’s expanded approval was based on data from the randomized, controlled MIRROR trial involving adults with uncontrolled gout. XTALKS WEBINAR: Beyond the EHR: Clinical Trials in the Age of Abundant Data.

FDA Approval 105

FDA Approval Antibody Trials Drugs 105

The Pharma Data

NOVEMBER 16, 2020

November 16, 2020 — An independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 reviewed trial data and shared its interim analysis with the trial oversight group on Nov. 37% of trial volunteers are from racial and ethnic minorities.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Roots Analysis

OCTOBER 13, 2023

As a result, in late nineties, the conjugation of drug with biological entities such as antibodies emerged as a possible solution for targeting earlier undruggable entities. However, it was not until 2000 when the first drug conjugate in the form of antibody drug conjugate (ADC) was approved by the USFDA.

Drugs 40

Drugs Antibody RNA Genetics 40

The Pharma Data

AUGUST 3, 2021

Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas Fast tracks establishment of Sanofi’s recently announced mRNA Center of Excellence Full integration upgrades drug formulation capabilities and enhances US talent in a promising new technology.

Vaccination 52

Vaccination Vaccine Development Licensing 52

The Pharma Data

JANUARY 31, 2021

Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. EMERYVILLE, Calif. and CHENGDU, China , Feb.

Vaccination 52

Vaccination Vaccine Trials Protein 52

Find Me Cure

OCTOBER 13, 2019

If you follow our blog you know that we at FindMeCure take updating our readership on treatments in development very seriously. There currently are drugs that do just that but now they’re in clinical trials for metastatic breast cancer as well. In phase II clinical trial, led by Steven A. Rosenberg, M.D.

Development 52

Development DNA Clinical Trials Clinical Trials 52

Roots Analysis

DECEMBER 12, 2023

As a result, innovators came up with the idea of magic bullets, antibody drug conjugates (ADCs). It is comprised of three components, namely antibody, drug and linker. The antibody is conjugated to the drug via a linker molecule. The antibody is conjugated to the drug via a linker molecule. Components of an ADC?

Antibody 40

Antibody Manufacturing Drugs RNA 40

pharmaphorum

SEPTEMBER 22, 2022

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s driving the development of new influenza and SARS-CoV-2 vaccines that attack T-cells, providing a long-lasting effect. One arm of the immune system triggers antibodies, and the other triggers T-cells.

Vaccination 97

Vaccination Vaccine Antibody Clinical Trials 97

pharmaphorum

OCTOBER 6, 2020

The European Medicines Agency has begun a second “rolling review” of a potential coronavirus vaccine jointly developed by BioNTech and Pfizer, setting up a race with a rival from AstraZeneca and Oxford University. In the case of a rolling review, the EMA evaluates trial data as they become available before a complete filing is submitted.

Vaccination 59

Vaccination Vaccine RNA Immune Response 59

The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. The full manuscript of the preclinical data is available on the pre-print server bioRxiv. “In

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

pharmaphorum

NOVEMBER 17, 2020

The vaccine developed in partnership with Germany’s BioNTech has been shown to be 90% effective in clinical trials. The company has picked four US states – Rhode Island, Texas, New Mexico and Tennessee, to trial a delivery programme that aims to overcome this challenge.

Vaccination 77

Vaccination Vaccine RNA Clinical Trials 77

pharmaphorum

NOVEMBER 23, 2020

AstraZeneca is preparing to file its COVID-19 vaccine with regulators after phase 3 trial results showed it is up to 90% effective. Results from trials conducted in the UK and Brazil showed an efficacy of 90% in 2,741 patients receiving the vaccine as a half dose, followed by a full dose at least one month apart.

Vaccination 105

Vaccination Vaccine Regulation Protein 105

pharmaphorum

NOVEMBER 21, 2022

Bomedemstat (IMG-7289) – an oral lysine-specific demethylase 1 (LSD1) inhibitor – is in multiple phase 2 trials for the treatment of indications including essential thrombocythemia (ET), myelofibrosis (MF), and polycythemia vera (PV). The acquisition is expected to close in the first quarter of 2023.

RNA 59

RNA Clinical Trials Clinical Trials Business Development 59

BioSpace

NOVEMBER 20, 2022

Former Theranos CEO Elizabeth Holmes will serve 11 years in prison on four counts of fraud, according to her sentencing by a federal judge in a California courtroom on Friday afternoon.

Antibody 75

Antibody Medicine Research Clinical Trials 75

pharmaphorum

DECEMBER 23, 2021

The first-in-class, small interfering RNA (siRNA) therapy for cholesterol lowering inhibiting PCSSK9 – the same target as Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Praluent (alirocumab) – but after a lead-in period is dosed only twice a year rather than every month.

Drugs 105

Drugs Sales Antibody FDA Approval 105

pharmaphorum

JANUARY 5, 2022

A COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone bio – has generated encouraging immune response data in its first clinical trial.

Protein 126

Protein Vaccination Vaccine Immune Response 126

The Pharma Data

DECEMBER 8, 2020

Since partnering with Eli Lilly to produce the first monoclonal antibody therapy approved for mild-to-moderate COVID-19 patients, antibody discovery company AbCellera is going big on the Nasdaq. Tackle the toughest problems in drug development.” The promise to partners is to “move quickly. Reduce cost. Silverback Therapeutics

RNA 52

RNA Antibody Life Science Protein 52

Drug Discovery World

JULY 11, 2023

Drug discovery and development timelines can span 10-15 years or more from initial discovery to market approval and typically require the analysis of massive amounts of data. How AI and ML are influencing drug development Biopharma has experienced significant growth in using these technologies for the past 10 years.

Big Data 40

Big Data Development Life Science Drugs 40

pharmaphorum

NOVEMBER 9, 2020

Top-line results come from a phase 3 trial of the candidate known as BNT162b2 and an evaluation of 94 cases from the trial of 43,538 patients. Results will be discussed with regulators worldwide and the European Medicines Agency has already begun its rolling review of data to hasten a decision on the clinical trial dossier.

Vaccination 98

Vaccination Vaccine Clinical Trials Clinical Trials 98

WCG Clinical

MAY 28, 2024

Today there are six CAR-T products with FDA approval for the treatment of multiple myeloma and B cell malignancies, with many related and next-generation products under development. If circulating antibody levels become too low, they may be supplemented with immunoglobulin therapy.

In-Vivo 52

In-Vivo Clinical Trials Clinical Trials FDA Approval 52

pharmaphorum

AUGUST 18, 2020

Could AI prevent future pandemics by developing an armoury of drugs that work against all coronaviruses? This is a question that a consortium of European pharma companies hopes to answer as it aims to rapidly develop new therapies to combat the pandemic. But also included in the 77.7

Protein 121

Protein Pharma Companies RNA Drugs 121

Drug Discovery World

APRIL 6, 2023

These topics will be represented across a range of session types, including methods workshops, minisymposia, poster and plenary sessions, as well as keynotes, awards and lectures.

Protein 52

Protein Antibody Clinical Trials Clinical Trials 52